NCT01289574 is a Phase 2 clinical trial of ASC-J9 in Acne, sponsored by AndroScience Corp.

Who is sponsoring NCT01289574?

NCT01289574 is sponsored by AndroScience Corp.

What drugs are being tested in NCT01289574?

Interventions in NCT01289574: ASC-J9.

Is NCT01289574 still recruiting?

NCT01289574 is currently completed. Last updated 29 July 2014.

Are results published for NCT01289574?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-07-29 · How we verify

NCT01289574

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of 0.1% and 0.025% ASC-J9 Creams Applied Topically Twice Daily for 12 Weeks for the Treatment of Facial Acne Vulgaris

Completed Phase 2 Results posted Last updated 29 July 2014

What this trial tests

Phase 2 trial testing ASC-J9 in Acne in 181 participants. Completed in 1 August 2012.

Timeline

1 February 2011

Primary endpoint
1 July 2012

1 August 2012

Quick facts

Lead sponsor	AndroScience Corp
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	181
Start date	1 February 2011
Primary completion	1 July 2012
Estimated completion	1 August 2012
Sites	7 locations across United States, Taiwan

Drugs / interventions tested

ASC-J9

Conditions studied

Acne — all drugs for Acne →

Sponsor

AndroScience Corp — full company profile →

Who can join

12 and older, any sex, with Acne. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percent Change in Inflammatory Acne Lesion Counts
Time frame: 12 weeks
Percent change from Baseline

Sponsor's own description

To evaluate the safety and efficacy of topical 0.1% and 0.025% ASC-J9 creams applied twice daily for facial acne compared to vehicle control.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases.
Kim MJ, Jeon JH. · · 2022 · cited 60× · PMID 35269986 · DOI 10.3390/ijms23052846
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer.
Chen QH, Munoz E, Ashong D. · · 2024 · cited 36× · PMID 38339414 · DOI 10.3390/cancers16030663
Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective.
Huang J, Lin B, Li B. · · 2022 · cited 35× · PMID 35372068 · DOI 10.3389/fonc.2022.865350
ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
Huang CP, Chen J, Chen CC, Liu G, et al · · 2019 · cited 17× · PMID 31234917 · DOI 10.1186/s13046-019-1258-0

Verify or expand the search:

Other recruiting trials for Acne

Currently open trials in the same condition.

NCT07366229 — Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne · Phase 2 · recruiting
NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
NCT06989840 — Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne · Phase 1 · recruiting
NCT07368764 — The Suitability of Tience® for Treating Acne Scars · NA · recruiting
NCT06909344 — 577-nm Diode Laser in the Treatment of Non -Inflammatory Acne · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01289574 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AndroScience Corp
Last refreshed: 29 July 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01289574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing